Base de dados : LILACS
Pesquisa : SP4.011.097.105.089 [Categoria DeCS]
Referências encontradas : 92 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 10 ir para página                        

  1 / 92 LILACS  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-1039048
Autor: Rodrigues, Leticia Norma Carpentieri; Tavares, Anna Carollina Moraes; Ferreira, Beatriz Tavares; Reis, Adriana Karla Cardoso Amorim; Katiki, Luciana Morita.
Título: Inclusion complexes and self-assembled cyclodextrin aggregates for increasing the solubility of benzimidazoles
Fonte: Braz. J. Pharm. Sci. (Online);55:e17776, 2019. tab, graf.
Idioma: en.
Resumo: Albendazole and fenbendazole are imidazole derivatives that exhibit broad spectrum activity against parasites, but the low solubility of these drugs considerably reduces their effectiveness. Complexation of albendazole and fenbendazole with cyclodextrins (ß-cyclodextrin and hydroxypropyl-ß-cyclodextrin) in both water and an aqueous solution of polyvinylpyrrolidone (PVP-k30) was studied to determine if it could increase the solubility and dissolution rate of the drugs. In an aqueous solution, ß-cyclodextrin increased the solubility of albendazole from 0.4188 to ~93.47 µg mL-1 (223×), and of fenbendazole from 0.1054 to 45.56 µg mL-1 (432×); hydroxypropyl-ß-cyclodextrin, on the other hand, increased solubility to ~443.06 µg mL-1 (1058×) for albendazole and ~159.36 µg mL-1 (1512×) for fenbendazole. The combination of hydroxypropyl-ß-cyclodextrin and polyvinylpyrrolidone enabled a solubility increase of 1412× (~591.22 µg mL-1) for albendazole and 1373× (~144.66 µg mL-1) for fenbendazole. The dissolution rate of the drugs was significantly increased in binary and ternary systems, with hydroxypropyl-ß-cyclodextrin proving to be more effective. The presence of the water-soluble PVP-k30 increased the dissolution rate and amorphization of the complexes. Analysis of the changes in displacement and the profile of the cyclodextrin bands in the 1H NMR spectra revealed a molecular interaction and pointed to an effective complexation in the drug/cyclodextrin systems. Monomeric forms and nanoclusters of cyclodextrins were observed in the drug/cyclodextrin systems, suggesting that the increase in solubility of the drugs in the presence of cyclodextrins should not be attributed only to the formation of inclusion complexes, but also to the formation of cyclodextrin aggregates
Descritores: Benzimidazóis/administração & dosagem
Ciclodextrinas/farmacocinética
Dissolução/classificação
-Solubilidade
Preparações Farmacêuticas
Albendazol/análise
Fenbendazol/análise
Antiparasitários/análise
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas


  2 / 92 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-998224
Autor: Martín Casanova-Godoy, Luis Antonio; Castillo-Saavedra, Ericson Félix; Reynoso-Leyva, Elva Milagros; Ayala-Jara, Carmen Isolina.
Título: Estudio comparativo de perfiles de disolución de tabletas de prednisona 20 mg comercializados en Perú / Comparative study of dissolution profiles of prednisone 20 mg tablets marketed in Peru
Fonte: Mem. Inst. Invest. Cienc. Salud (Impr.);16(3):13-21, dic. 2018. tab, ilus.
Idioma: es.
Resumo: El estudio tuvo como finalidad comparar los perfiles de disolución de tabletas de prednisona 20 mg comercializados en Perú. Se realizó un estudio cuantitativo comparativo con diseño no experimental, que incluyó doce tabletas para cada formulación a evaluar (referente y multifuente), bajo condiciones similares de trabajo, en tres medios de disolución: buffer ácido clorhídrico pH 1,2; buffer acetato pH 4,5 y buffer fosfato pH 6,8. Los porcentajes temporales disueltos de prednisona fueron evaluados mediante el orden cinético cero, uno, Higuchi, raíz cúbica y Weibull para el modelo dependiente; mientras que el factor de similitud (f2), tiempo medio de disolución y eficiencia de disolución fueron utilizados para el modelo independiente. En el modelo dependiente, la liberación de prednisona; se ajustó a la cinética de función de Weibull; evaluada mediante el criterio de información de Akaike. En el modelo independiente, los valores de f2 en todos los medios de disolución cumplieron con el rango 50 - 100 establecida por la Food and Drug Adminstration, para indicar similitud in vitro entre los perfiles de disolución. Asimismo, se evidenció que no existe diferencia estadísticamente significativa entre las formulaciones, respecto al tiempo medio de disolución y la eficiencia de disolución. Las tabletas de prednisona 20 mg referente y multifuente comercializados en Perú son similares, con base en pruebas de perfiles de disolución in vitro(AU)

The purpose of the study was to compare the dissolution profiles of prednisone 20 mg tablets marketed in Peru. A comparative quantitative study with a non-experimental design was carried out, which included twelve tablets for each formulation to be evaluated (referent and multi-source), under similar work conditions in three dissolution media: hydrochloric acid buffer pH 1.2, acetate buffer pH 4.5 and phosphate buffer pH 6.8. The dissolved temporal percentages of prednisone were evaluated by zero kinetic order and first kinetic order, Higuchi, cubic root and Weibull models for the dependent model; while the similarity factor (f2), mean dissolution time and dissolution efficiency were used for the independent model. In the dependent model, the release of prednisone was adjusted to the Weibull function kinetics, evaluated using the Akaike information criterion. In the independent model, the values of f2 in all the dissolution media fulfilled the range 50 - 100 established by the Food and Drug Administration, to indicate in vitro similarity between the dissolution profiles. Likewise, it was evidenced that there is no statistically significant difference between the formulations with respect to the mean dissolution time and the dissolution efficiency. The reference and multi-source prednisone 20 mg tablets marketed in Peru are similar based on in vitro dissolution profiles tests(AU)
Descritores: Prednisona/farmacocinética
Liberação Controlada de Fármacos
Glucocorticoides/farmacocinética
-Peru
Comprimidos
Técnicas In Vitro
Dissolução
Tipo de Publ: Estudo Comparativo
Responsável: PY3.1 - Biblioteca


  3 / 92 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Id: biblio-1008055
Autor: Fretes-de Aquino, Sonia Lorena; Coronel, Ma. Belén; Armoa, Evelyn; Fernández, Emile L; Vera, Rocio; Cho-Kim, Chang Kun; Benítez, Lourdes A; Villamayor, Melissa; Chena, Loren L; González, Andrea A; Sanabria, Lorena E.
Título: Evaluación de la Calidad vs precio de comprimidos de Metformina de 850mg de producción nacional e importados, comercializados en Paraguay utilizados para el control de diabetes / Quality vs. price evaluation of national and imported 850 mg metformin tablets marketed for the control of diabetes in Paraguay
Fonte: Mem. Inst. Invest. Cienc. Salud (Impr.);17(1):93-98, abr. 2019. tab, ilus.
Idioma: es.
Resumo: La metformina es un fármaco de primera elección, solo o combinado, en el tratamiento inicial de pacientes con diabetes tipo 2, cuya prevalencia a nivel nacional es de 8,0% en hombres y 8,3% en mujeres, con un gasto anual de 283 USD/persona. El estudio fue realizado con el objetivo de evaluar la calidad fisicoquímica y precio de comprimidos de 850 mg de metformina comercializados en nuestro país. Se analizaron medicamentos de producción nacional e importada, conteniendo 850 mg de metformina HCl, tomando como referencia la Farmacopea de los Estados Unidos (USP 38). Para evaluar la calidad de los productos se realizaron ensayos físicos químicos, además de los perfiles de disolución según el medio propuesto por la USP 38. Los resultados obtenidos se encontraron dentro de las especificaciones de valoración, entre 96% y 101% de metformina y los perfiles de disolución entre 70% y 90% de la cantidad declarada en 20 minutos, con una eficiencia de disolución (EF) entre 58% y 93%, mostrando que no existe diferencia estadísticamente significativa (p=0,41). La variación de precios encontrados fue entre 3,6 USD y 8,4 USD. Los productos analizados pueden ser intercambiables en cuanto a la calidad y los perfiles de disolución in vitro, siendo una herramienta para demostrar intercambiabilidad de productos farmacéuticos, buscando el precio más accesible en el mercado nacional y facilitando el tratamiento adecuado sobre todo para la población de escasos recursos manteniendo la calidad y eficacia del mismo(AU)
Descritores: Preço de Medicamento
Diabetes Mellitus Tipo 2/tratamento farmacológico
Avaliação de Medicamentos
Hipoglicemiantes/uso terapêutico
Metformina/uso terapêutico
-Paraguai
Comprimidos
Dissolução
Hipoglicemiantes/análise
Metformina/análise
Responsável: PY3.1 - Biblioteca


  4 / 92 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-1049803
Autor: Sevillano, Eduard Diego Alonso Aroca.
Título: Desenvolvimento de metodologia para avaliação do perfil de dissolução de comprimidos de atorvastatina cálcica 20 mg comercializados no Peru, Brasil e Bolívia / Development of a methodology to evaluate the dissolution profile of atorvastatin calcium tablets 20 mg marketed in Peru, Brazil and Bolivia.
Fonte: São Paulo; s.n; 2019. 93 p. tab, graf.
Idioma: pt.
Tese: Apresentada a Universidade de São Paulo. Faculdade de Ciências Farmacêuticas para obtenção do grau de Mestre.
Resumo: O presente estudo teve por finalidade desenvolver uma metodologia de dissolução discriminativa para avaliar comprimidos contendo diferentes polimorfos de atorvastatina cálcica (ATR). Este trabalho é conformado por quatro capítulos, no qual o primeiro apresenta uma breve revisão de literatura sobre as características dos polimorfos da ATR, abordando-se informações mais relevantes sobre o ATR em relação ao polimorfismo e sua influência na biodisponibilidade. No segundo capítulo, apresenta-se a importância da caracterização dos polimorfismos e suas implicações para a ATR. As amostras de ATR foram identificadas por difração raio X e análise térmica e, posteriormente, demonstrou-se as diferenças entre quatro amostras comercializadas no mercado brasileiro relacionadas ao hábito cristalino, tamanho de partícula e solubilidade. No terceiro capítulo, demonstra-se o desenvolvimento do método de dissolução discriminativo para comprimidos contendo duas formas polimórficas da ATR. Para tanto, avaliou-se a solubilidade destas pelo método do equilíbrio e determinou-se as condições experimentais mais adequadas para o ensaio de dissolução por intermédio de planejamento fatorial completo do tipo 23, sendo as variáveis independentes o meio de dissolução, a velocidade de agitação e as formas polimórficas (I e VIII). Os resultados obtidos foram tratados estatisticamente através da análise de variância, dos gráficos de Pareto e de superfície de resposta. Concluiu-se que a velocidade de agitação e o meio de dissolução impactam os resultados, afetando a dissolução das formulações com os polimorfos avaliados. Assim, as condições selecionadas foram: 750 mL de meio água a 65 rpm. Após o desenvolvimento do método, este foi comparado com o da Food and Drug Administration (FDA) para comprimidos de atorvastatina cálcica. Ao final dos ensaios, o método desenvolvido mostrou-se adequado para apontar diferenças entre os polimorfos da ATR. No quarto capítulo, o método desenvolvido foi utilizado para avaliar o perfil de dissolução de comprimidos comercializados em três países sul-americanos: Brasil, Peru e Bolívia. As porcentagens de fármaco dissolvidas e a Eficiência de Dissolução foram as variáveis estudadas e, posteriormente, tratadas estatisticamente através da análise de componentes principais, sendo possível comparar o perfil de dissolução de dessete formulações. Dessa forma, foi possível concluir que cinco formulações avaliadas (BR1, BR2 PE6, BR7 e BO3) possuíam a forma polimórfica VIII, enquanto duas formulações (BR5 e PE2) continham a forma polimórfica I. As demais, possivelmente, apresentam misturas ou outras formas polimórficas

This present study was aimed at developing a discriminative dissolution methodology to evaluate tablets containing different calcium atorvastatin (ATR) polymorphs. This paper consists of four chapters. The first chapter presents a brief literature review of the characteristics of ATR polymorphs, and addresses more relevant information about ATR in relation to polymorphism and its influence on bioavailability. The second chapter presents the importance of the characterization of polymorphs and their implications for ATR. The ATR samples were identified by X-ray diffraction and thermal analysis. Subsequently, the differences among the four samples marketed in the Brazilian market with relation to crystalline habit, particle size and solubility were demonstrated. The third chapter demonstrates the development of the discriminative dissolution method for tablets containing two polymorphic forms of ATR. For this, their solubilities were evaluated by the equilibrium method and the most suitable experimental conditions for the dissolution test were determined by means of complete factorial design of type 23, and the independent variables were the dissolution medium, the stirring speed and polymorphic forms (I and VIII). The results obtained were statistically treated through analysis of variance, Pareto and response surface graphs. It was concluded that the stirring speed and the dissolution medium influenced the results, affecting the dissolution of the formulations with the evaluated polymorphs. Thus, the selected condition was 750 mL of water at 65 rpm. Following the development of the method, it was compared with that of the Food and Drug Administration (FDA) for atorvastatin calcium tablets. At the end of the tests, the developed method was adequate to point out differences between the ATR polymorphs. In the fourth chapter, the developed method was used to evaluate the dissolution profile of tablets marketed in three South American countries: Brazil, Peru and Bolivia. Dissolved drug percentages and Dissolution Efficiency were the studied variables and statistically treated by principal component analysis. Through this method, it was possible to compare the dissolution profile of seventeen formulations. Thus, it was possible to conclude that five formulations evaluated (BR1, BR2, PE6, PE7 e BO3) had the polymorphic form VIII, while two formulations (BR5 e PE2) contained the polymorphic form I. The others possibly have mixtures or other forms polymorphic
Descritores: Peru/etnologia
Comprimidos/análise
Bolívia/etnologia
Brasil/etnologia
Dissolução/métodos
Atorvastatina Cálcica/análise
-Polimorfismo Genético
Comercialização de Medicamentos
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas
BR40.1; T615.4, A769d. 30100022666-F


  5 / 92 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
Id: biblio-1048832
Autor: Leon, Rosmery Merma.
Título: Combinação dose fixa de hidroclorotiazida (12, 5 mg) e valsartana (160 mg): Desenvolvimento de metodologia de dissolução in vitro e in silico para avaliar os perfis de dissolução dos produtos comercializados no Brasil e Peru / Fixed dose combination of hydrochlorothiazide (12. 5 mg) and valsartan (160 mg): Development of in vitro and in silico dissolution methodology to evaluate the dissolution profiles of products marketed in Brazil and Peru.
Fonte: São Paulo; s.n; 2019. 98 p. tab, graf.
Idioma: pt.
Tese: Apresentada a Universidade de São Paulo. Faculdade de Ciências Farmacêuticas para obtenção do grau de Mestre.
Resumo: Hidroclorothiazida (HTZ) e valsartana (VAL) são fármacos pouco solúveis em meio aquoso e pertencem às classes IV e II do Sistema de Classificação Biofarmacêutica (SCB), respectivamente. O objetivo deste trabalho foi desenvolver um método para avaliar o perfil de dissolução de formas farmacêuticas sólidas de dose fixa combinada contendo HTZ (12,5 mg) e VAL (160 mg) usando ferramentas in silico para avaliar os perfis de dissolução de produtos comercializados no Brasil e Peru. O presente trabalho foi dividido em 4 capítulos. No Capítulo I, foi determinada a solubilidade da HTZ e VAL pelo método shake-flask e potenciométrico, no qual foi possível demonstrar que existe correlação entre ambos os métodos e que HTZ e VAL são solúveis em tampão fosfato pH 6,8. No Capítulo II, um método cromatográfico em HPLC foi desenvolvido com base em Quality by Design (QbD), com auxílio do software Fusion®, no qual foi estabelecido uma zona de confiança dos parâmetros, que garantiu a robustez do método. O Capítulo III descreve o desenvolvimento de um método de dissolução utilizando ferramenta in silico (DDDplus®) na qual foi definido um delineamento experimental do tipo fatorial completo 33 usando como fatores a formulação, utilização de âncora e velocidade de agitação. Para os ensaios de dissolução in vitro, foi proposto um outro delineamento fatorial 3(3-1) com o intuito de obter as constantes de calibração das simulações in silico. Através de uma análise estatística das eficiências de dissolução obtidas nas simulações, foram avaliados os efeitos e as interações entre os fatores. Assim, as condições finais do método de dissolução estabelecidas foram: 900 mL de tampão fosfato pH 6,8 como meio de dissolução, 75 rpm de velocidade de agitação, e utilização de âncora para evitar a flutuação das formulações. O método desenvolvido foi empregado, no contexto do Capítulo IV, para avaliar o perfil de dissolução dos produtos contendo HTZ e VAL comercializados no Brasil e no Peru. Por análise multivariada, a eficiência de dissolução (ED), tempo médio de dissolução (MDT) e as porcentagens de dissolução de 5 até 60 minutos foram utilizadas para agrupar as formulações em grupos distintos. Embora os perfis de dissolução mostrem similaridade entre todas as formulações avaliadas, o produto referência se destacou por apresentar uma maior ED comparado com as outras formulações, devido à maior liberação nos primeiros 5 minutos de ensaio. Concluiu-se que o método proposto, além de garantir a liberação total de HTZ e VAL a partir das formulações, possui adequado poder discriminativo

Hydrochlorothiazide (HTZ) and valsartan (VAL) are poorly soluble drugs in aqueous medium and belong to classes IV and II of the Biopharmaceutical Classification System (BCS), respectively. The objective of this study was to develop a dissolution method to evaluate the dissolution profile of solid pharmaceutical forms of combined dose containing HTZ (12.5 mg) and VAL (160 mg) using in silico tools to evaluate the dissolution profiles of products sold in Brazil and Peru. The present study was divided into four chapters. In Chapter I, the HTZ and VAL solubility were determined by the shake-flask and potentiometric methods, in which it was possible to demonstrate that there is a correlation between both methods and that HTZ and VAL are soluble in pH 6.8 phosphate buffer. In Chapter II, a chromatographic method in HPLC was developed based on Quality by Design (QbD), using the Fusion® software, in which a zone of confidence of the parameters was established, which ensured the robustness of the method. Chapter III presents the development of a dissolution method using in silico (DDDplusTM) as a tool, in which an experimental design of the complete factorial type 33 was defined using as factors: the formulation, use of sinker and agitation speed. For in vitro dissolution assays, another factor design 3(3-1) was proposed to obtain the calibration constants of the in silico simulations. Through a statistical analysis of the dissolution efficiencies obtained in the simulations, the effects and interactions between the factors were evaluated. Thus, the final conditions of the dissolution method established were: 900 mL of pH 6.8 phosphate buffer as a dissolution medium, 75 rpm of stirring speed, and use of sinker to avoid the fluctuation of the formulations. The method developed was used, in the context of Chapter IV, to evaluate the dissolution profile of HTZ and VAL products marketed in Brazil and Peru. By multivariate analysis, the dissolution efficiency (ED), mean dissolution time (MDT) and the dissolution percentages from 5 to 60 minutes were used to group the formulations in different groups. Although the dissolution profiles show a similarity between all the evaluated formulations, the reference product stood out for presenting a higher ED compared to the other formulations, due to the higher release in the first 5 minutes of the test. It was concluded that the proposed method, besides guaranteeing the total release of HTZ and VAL from the formulations, has adequate discriminatory capacity
Descritores: Peru
Técnicas In Vitro/instrumentação
Brasil
Dissolução/análise
Valsartana/farmacocinética
Hidroclorotiazida/farmacocinética
-Solubilidade/efeitos dos fármacos
Simulação por Computador/classificação
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas
BR40.1; T615.4, L579c. 30100022645-F


  6 / 92 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Araújo, Magali Benjamim de
Texto completo
Texto completo
Id: biblio-1039059
Autor: Ângelo, Marilene Lopes; Ruela, André Luís Morais; Ferreira, Anna Clara Marques; Ramos, Marcus Vinicus de Faria; Montanari, Cristina Martiniano; Silva, Lucélia Magalhães da; Araújo, Magali Benjamim de.
Título: Evaluating the discriminatory power of a dissolution assay for rosuvastatin calcium capsules: Solid-state properties and dissolution media
Fonte: Braz. J. Pharm. Sci. (Online);55:e17520, 2019. tab, graf.
Idioma: en.
Projeto: Fundação de Amparo à Pesquisa do Estado de Minas Gerais.
Resumo: We propose to evaluate the dissolution properties of rosuvastatin calcium (ROSC) capsules in different media to characterize the discriminatory power of the assay method. Dissolution assays were performed in media with different pH, and including the surfactant sodium dodecyl sulfate (SDS). Several immediate-release formulations were manufactured using the commercial raw material characterized as amorphous solid. The hydrophobic adjutant magnesium stearate was employed in some formulations due to its negative effect in the wettability and dissolution efficacy of solid dosages. These formulations showed the lower dissolution efficacy values in media without surfactant; however, when SDS was added to the medium, the dissolution efficacy increased, and the discriminatory power was lost. In spite of micellar solubilization does not increase the ROSC solubility, it modifies the discriminatory power of the assay method, increasing the wettability of the powder mixtures. The crystalline form M of ROSC was recrystallized in our laboratory, and it showed lower solubility in water than amorphous solid. However, its dissolution properties were not influenced by SDS. These results are important to develop dissolution assays for other hydrophilic drugs with increased water solubility, once that dissolution media with surfactants increase the wettability of the formulations, leading to an overrated dissolution rate.
Descritores: Cápsulas/análise
Dissolução/análise
Rosuvastatina Cálcica/análise
-Solubilidade
Cromatografia Líquida de Alta Pressão/instrumentação
Formas de Dosagem
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas


  7 / 92 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-889421
Autor: Bonfilio, Rudy; Souza, Marília Cristina Oliveira; Leal, Jockastta Silva; Viana, Olímpia Maria Martins Santos; Doriguetto, Antônio Carlos; Araújo, Magali Benjamin de.
Título: Solubility and dissolution studies of tibolone polymorphs
Fonte: Braz. J. Pharm. Sci. (Online);53(4):e00233, 2017. tab, graf, ilus.
Idioma: en.
Projeto: FAPEMIG; . FINEP; . CAPES; . CNPq.
Resumo: ABSTRACT Different solid forms of an active pharmaceutical ingredient can have distinct chemical and physical characteristics. In this work, we studied the solubility and dissolution properties of the described tibolone polymorphic forms (I and II). Both forms were successively recrystallized and characterized by powder X-ray diffraction and attenuated total reflection infrared spectroscopy. Equilibrium solubility and dissolution profiles were performed for both forms. Solubility studies demonstrated that form II is statistically more soluble in water, 0.01 mol L-1 HCl and pH 4.5 acetate buffer. The solubility of forms I and II were explained in terms of crystal packing. Dissolution tests of tablets showed a lower release of polymorphic form II than form I from tablets. The results showed an impact of polymorphism on the quality of tibolone tablets and suggest that tibolone forms I and II can show distinct interactions with pharmaceutical excipients used in tablets. Therefore, only form I is acceptable for the preparation of tablet forms. Based on our results, we propose the quality control on tibolone raw materials using X-ray diffraction analysis and attenuated total reflection infrared spectroscopy.
Descritores: Solubilidade/efeitos dos fármacos
Dissolução/análise
-Análise Espectral
Comprimidos/normas
Difração de Raios X/métodos
Preparações Farmacêuticas/normas
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas


  8 / 92 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-1001579
Autor: Shaheen, Nabeela; Zaman, Shahiq uz.
Título: Development of fast dissolving tablets of flurbiprofen by sublimation method and its in vitro evaluation
Fonte: Braz. J. Pharm. Sci. (Online);54(4):e17061, 2018. tab, graf.
Idioma: en.
Resumo: Flurbiprofen belongs to Biopharmaceutical Classification System (BCS) class II drugs which are poorly soluble in water. The objective of present research work was to prepare fast dissolving tablets of Flurbiprofen using varying concentrations of three different sublimating agents to improve the dissolution rate. Seven formulations were prepared containing different concentrations of camphor, ammonium bicarbonate and thymol as sublimating agent along with primogel as a superdisintegrant. Tablets were manufactured by direct compression method. The prepared tablets were evaluated for pre-compression and post-compression parameters result, For all formulations result was within official limits. FTIR studies revealed that there were no interactions between the drug and the excipients used. From in vitro drug release studies it was concluded that the formulations F6 and F7 containing 10% and 15% of thymol showed fast drug release of 100.00% and 100.84% respectively in 30 minutes. Formulations containing camphor (F2 & F3) and ammonium bicarbonate (F4 & F5) as sublimating agents showed a drug release of less than 80%, while the control formulation F1 having no sublimating agent showed 49.14% of drug release in 30 minutes. Thus thymol can successfully be used to formulate fast dissolving tablets of flurbiprofen by sublimation method with much better dissolution profile
Descritores: Comprimidos/farmacologia
Técnicas In Vitro
Flurbiprofeno/análise
Dissolução/análise
-Liberação Controlada de Fármacos
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas


  9 / 92 LILACS  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-1001567
Autor: Sankari, Thaeer; Al-Hariri, Sahar.
Título: Preparation and characterization of cefuroxime axetil solid dispersions using poloxamer 188
Fonte: Braz. J. Pharm. Sci. (Online);54(4):e17644, 2018. tab, graf.
Idioma: en.
Resumo: The main objective of the present work was to enhance the solubility and dissolution rate of poorly water-soluble drug cefuroxime axetil (CA) by formulating it into solid dispersions (SDs) with water soluble carrier poloxamer 188. Different methods were employed to prepare the dispersion, such as: Solvent method (SM), Kneading method (KM), Melt evaporation method (MEM) and Physical mixture (PM) in different drug: carrier ratios 1:1, 1:2 and 1:3 (cefuroxime axetil: poloxamer 188). The physical mixture(s) and solid dispersion(s) were characterized for drug carrier interaction, drug content, solubility, dissolution rate, differential scanning calorimetry (DSC) and FT-IR study. The dissolution rate of the prepared solid dispersion systems was determined in phosphate buffer (pH 6.8) for 1 h. The solubility of drug from different systems was also determined in water. All SD formulations were found to have a higher dissolution rate comparatively to pure CA. The dissolution rate was enhanced in the following order SM > MEM > KM. The enhancement of dissolution rate may be caused by increase wettability, dispersibillity reduction in particle size or the formation of CA ß crystalline. The FT-IR study probability revealed that there was no chemical interaction between drug and poloxamer 188
Descritores: Solubilidade
Cefuroxima/agonistas
Dissolução/análise
-Poloxâmero/administração & dosagem
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas


  10 / 92 LILACS  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
Texto completo
Texto completo
Id: biblio-889424
Autor: Toehwé, Leonardo Henrique; Prado, Livia Deris; Rocha, Helvécio Vinícius Antunes.
Título: Prednisone raw material characterization and formulation development
Fonte: Braz. J. Pharm. Sci. (Online);53(4):e00088, 2017. tab, graf, ilus.
Idioma: en.
Resumo: ABSTRACT Solid dosage forms for oral use, particularly tablets, are the most highly used dosage forms in therapy because they are easily administered, have high productivity and relatively low cost and provide a more stable drug to form a semi-solid net. Numerous parameters influence the quality of the final dosage form. In this study, the dissolution profile of 20-mg prednisone tablets bioequivalent to the reference product and three test formulations were evaluated using stability testing. During the study, prednisone tablets and the active pharmaceutical ingredient (API) prednisone from two different manufacturers were characterized with respect to their physical and physicochemical properties. The results showed that the dissolution profiles of the test batches and the reference product did not retain pharmaceutical equivalence throughout all the stability study. Notably, both samples of API prednisone were of the same crystal form, and any phase transition that occurred during the study could not be attributed to dissolution variation during stability.
Descritores: Prednisona/administração & dosagem
Estabilidade de Medicamentos
Dissolução/análise
-Preparações Farmacêuticas/normas
Propriedades Físicas e Químicas
Dosagem
Responsável: BR40.1 - DBD - Divisão de Biblioteca e Documentacão do Conjunto das Químicas



página 1 de 10 ir para página                        
   


Refinar a pesquisa
  Base de dados : Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde